DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,871 filers reported holding DANAHER CORPORATION in Q3 2021. The put-call ratio across all filers is 1.50 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,289,142,212 | +59.0% | 9,226,691 | +53.8% | 0.25% | +62.2% |
Q2 2023 | $1,439,347,810 | +58.9% | 5,997,282 | +66.9% | 0.16% | +41.8% |
Q1 2023 | $905,729,090 | +118531.1% | 3,593,589 | +24.9% | 0.11% | +8.9% |
Q4 2022 | $763,484 | -99.9% | 2,876,515 | -6.3% | 0.10% | -11.4% |
Q3 2022 | $792,797,000 | -11.6% | 3,069,401 | -13.3% | 0.11% | -8.8% |
Q2 2022 | $897,289,000 | +23.8% | 3,539,322 | +43.2% | 0.12% | +43.7% |
Q1 2022 | $724,871,000 | +30.5% | 2,471,181 | +46.3% | 0.09% | +35.9% |
Q4 2021 | $555,554,000 | -4.6% | 1,688,563 | -11.8% | 0.06% | -11.1% |
Q3 2021 | $582,545,000 | +55.9% | 1,913,496 | +37.4% | 0.07% | +60.0% |
Q2 2021 | $373,760,000 | +35.0% | 1,392,752 | +13.2% | 0.04% | +21.6% |
Q1 2021 | $276,862,000 | -34.6% | 1,230,065 | -35.5% | 0.04% | -40.3% |
Q4 2020 | $423,391,000 | +29.5% | 1,905,959 | +23.0% | 0.06% | +12.7% |
Q3 2020 | $327,023,000 | +106.6% | 1,549,798 | +73.1% | 0.06% | +77.4% |
Q2 2020 | $158,292,000 | +40.1% | 895,151 | +9.6% | 0.03% | +14.8% |
Q1 2020 | $113,020,000 | -36.9% | 816,555 | -30.0% | 0.03% | -18.2% |
Q4 2019 | $179,061,000 | -8.2% | 1,166,675 | -13.6% | 0.03% | -15.4% |
Q3 2019 | $195,084,000 | +3.3% | 1,350,728 | +1.5% | 0.04% | +5.4% |
Q2 2019 | $188,877,000 | -24.9% | 1,330,316 | -30.2% | 0.04% | -27.5% |
Q1 2019 | $251,479,000 | +1.6% | 1,904,842 | -20.7% | 0.05% | -10.5% |
Q4 2018 | $247,630,000 | -33.5% | 2,401,386 | -29.9% | 0.06% | -19.7% |
Q3 2018 | $372,344,000 | +24.9% | 3,426,709 | +13.5% | 0.07% | +16.4% |
Q2 2018 | $298,003,000 | +9.9% | 3,019,892 | +9.1% | 0.06% | +5.2% |
Q1 2018 | $271,137,000 | -7.5% | 2,769,245 | -12.3% | 0.06% | -6.5% |
Q4 2017 | $293,043,000 | +14.4% | 3,157,105 | +4.8% | 0.06% | +8.8% |
Q3 2017 | $256,136,000 | +87.5% | 3,011,947 | +86.1% | 0.06% | +83.9% |
Q2 2017 | $136,610,000 | -8.3% | 1,618,782 | -7.1% | 0.03% | -8.8% |
Q1 2017 | $149,055,000 | +28.5% | 1,742,735 | +16.9% | 0.03% | +21.4% |
Q4 2016 | $116,039,000 | -45.5% | 1,490,749 | -45.1% | 0.03% | -46.2% |
Q3 2016 | $212,748,000 | -8.3% | 2,713,981 | +18.1% | 0.05% | -10.3% |
Q2 2016 | $232,088,000 | +39.5% | 2,297,894 | +31.0% | 0.06% | +34.9% |
Q1 2016 | $166,420,000 | -0.9% | 1,754,374 | -3.0% | 0.04% | +2.4% |
Q4 2015 | $167,997,000 | +387.7% | 1,808,760 | +347.4% | 0.04% | +366.7% |
Q3 2015 | $34,450,000 | -68.2% | 404,284 | -68.1% | 0.01% | -65.4% |
Q2 2015 | $108,343,000 | +35.7% | 1,265,848 | +34.6% | 0.03% | +44.4% |
Q1 2015 | $79,840,000 | -74.9% | 940,392 | -74.7% | 0.02% | -75.3% |
Q4 2014 | $317,987,000 | -12.7% | 3,710,013 | -22.6% | 0.07% | -15.1% |
Q3 2014 | $364,210,000 | +241.5% | 4,793,514 | +253.9% | 0.09% | +218.5% |
Q2 2014 | $106,639,000 | +31.1% | 1,354,476 | +24.9% | 0.03% | +22.7% |
Q1 2014 | $81,337,000 | +28.6% | 1,084,459 | +32.3% | 0.02% | +22.2% |
Q4 2013 | $63,272,000 | -39.8% | 819,611 | -45.9% | 0.02% | -41.9% |
Q3 2013 | $105,026,000 | +9.0% | 1,515,069 | -0.5% | 0.03% | 0.0% |
Q2 2013 | $96,358,000 | – | 1,522,266 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |